Caution required for biosimilars

While they present a cost-saving opportunity, safety data on biosimilars is still limited, warns IBD specialist There is an absence of data on adverse reactions or potential development of anti-drug antibodies caused by the use of biosimilars, warns Dr Greg Moore, Head of IBD at Monash Medical Centre in Melbourne and a Senior Lecturer in